Development of an Investigational New Drug for the treatment of pancreatic cancer

开发治疗胰腺癌的研究性新药

• 批准号: 101364
• 金额: $ 227.6万
• 依托单位: SENTINEL ONCOLOGY LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101364
• 关键词: Development; Investigational; New; Drug; treatment

There is a continuing need for new and more effective medicines to treat cancer patients. Despite a steady increase in the number of clinical treatment options available to patients, the number of people being diagnosed with cancer is growing.Sentinel Oncology is a company dedicated to the design and development of new and innovative approaches for the treatment of cancer. The objective of this project is to identify a new drug suitable for the treatment of pancreatic cancer, a disease with very few, if any suitable treatments currently available and for which the prognosis for patients is extemely poor.The successful completion of this project will allow clinicians to develop clinical trials which will be designed to safely enhance the anti-cancer effects of current standards of care for pancreatic cancer.

持续需要新的和更有效的药物来治疗癌症患者。尽管可供患者选择的临床治疗方案数量稳步增加，但被诊断患有癌症的人数也在增加。Sentinel Oncology是一家致力于设计和开发新的创新癌症治疗方法的公司。该项目的目的是确定一种适用于治疗胰腺癌的新药，胰腺癌是一种目前几乎没有合适治疗方法的疾病，患者的预后非常差。该项目的成功完成将使临床医生能够开展临床试验，旨在安全地增强目前胰腺癌治疗标准的抗癌效果。